Resverlogix Corporation
4820 Richard Road SW
Suite 300
Calgary
Alberta
T3E 6L1
Canada
Tel: 403-254-9252
Fax: 403-256-8495
Website: http://www.resverlogix.com/
Email: info@resverlogix.com
250 articles about Resverlogix Corporation
-
Resverlogix Announces Filing Of Quarterly Financial Statements And Management's Discussion & Analysis
9/15/2016
-
Resverlogix Announces Participation In Upcoming Conferences
9/12/2016
-
Resverlogix Hosts Symposium To Discuss The Role Of BET-Inhibition In Modifying Cardiovascular Risk At The European Society of Cardiology Congress In Rome, Italy
8/31/2016
-
Resverlogix Hosts Symposium To Discuss The Role Of BET-Inhibition In Modifying Cardiovascular Risk At The European Society of Cardiology Congress In Rome, Italy
8/29/2016
-
Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study Of Apabetalone (RVX-208)
8/11/2016
-
Resverlogix Files 2016 Year-End Disclosure Documents
7/28/2016
-
Resverlogix Announces Dosing Of First Two Patients In Expanded Renal And Orphan Programs
7/22/2016
-
Resverlogix Announces Corporate Update Webcast
6/9/2016
-
BIO2016: Resverlogix Announces Lead Drug Apabetalone Publication And Presentation At BIO International 2016
6/2/2016
-
Resverlogix Presents New Complement Data And Establishes Renal Clinical Advisory Board At The 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
5/25/2016
-
The New York Academy of Sciences Collaborates With Resverlogix To Host Epigenetics Symposium
4/18/2016
-
Resverlogix Further Strengthens The Board Of Directors And Appoints A New Chairman
4/4/2016
-
Resverlogix Announces Corporate Update Webcast
3/2/2016
-
Resverlogix's Manuscript On BET-Inhibitor apabetalone (RVX-208) Accepted Into The Atherosclerosis Journal
1/26/2016
-
Resverlogix Commences Dosing In Phase 3 Clinical Trial Betonmace
11/11/2015
-
Resverlogix Presents Important New Data At The Annual American Society of Nephrology Kidney Week Conference
11/9/2015
-
Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
10/26/2015
-
Resverlogix Selected To Present At Cavendish Global Health Impact Forum
10/22/2015
-
Resverlogix Announces Voting Results
10/1/2015
-
Resverlogix Provides Research And Development Update In New York City
9/29/2015